Engineered immune cells take aim at Hard-to-Treat lupus nephritis
NCT ID NCT07517536
First seen Apr 20, 2026 · Last updated Jun 06, 2026 · Updated 8 times
Summary
This early study tests a new treatment called CHT105 for people with lupus nephritis that hasn't improved with standard care. CHT105 uses donor immune cells engineered to find and destroy the faulty immune cells driving the disease. Fourteen adults will receive a single infusion after a short chemotherapy prep, then be followed for a year to check safety and kidney response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
Conditions
Explore the condition pages connected to this study.